



- *Medical Director, Clinical Research Services*
- *Co-Director, Adult Cystic Fibrosis Program*
- *Director, Cystic Fibrosis Therapeutics Development Center Adult Program*
- *Professor*
- *Division of Pulmonary, Critical Care & Sleep Medicine*
- *Department of Medicine*
- *Division of Pediatric Pulmonary Medicine*
- *Department of Pediatrics*

#### Conditions Treated:

- *Cystic Fibrosis (CF)*
- *Pediatric Lung Disease*

#### Research Areas:

- *Cystic Fibrosis (CF)*

#### Programs & Services:

- *Bronchiectasis Treatment Program*
- *Department of Medicine*
- *Cystic Fibrosis Program (Adult)*
- *Pulmonary Diagnostic Center (Pediatric)*
- *Adult Cystic Fibrosis Clinic*
- *Division of Pulmonary, Critical Care and Sleep Medicine (Adult)*
- *National Jewish Health for Kids / Pediatric Programs*
- *Division of Pediatric Pulmonary Medicine*

#### Research Interests

Cystic Fibrosis, innate immunity, CFTR function, clinical research

#### Board Certification

11/2008: ABP, Subspecialty in Pediatric Pulmonary  
10/2006: ABIM, Subspecialty in Pulmonary Disease  
8/2004: American Board of Internal Medicine  
8/2002: American Board of Pediatrics

#### Education

1993 Stanford University (Stanford, CA), BA, Human Biology  
1998 Duke University Medical Center (Durham, NC), MD

#### Residency

1998 - 2002 Duke University Medical Center, Internal Medicine and Pediatrics

#### Fellowship

2002 - 2006 Duke University Medical Center, Adult and Pediatric Pulmonary Medicine

#### Teaching or Professional Positions

2012: Board Member, Colorado CFF Chapter  
5/2009-Present: American Thoracic Society  
2010: Clinical Problems Program Committee

#### Affiliations with the University of Colorado Denver

2009-Present: Professor, Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine and the Department of Pediatrics, Pulmonary Division, University of Colorado Denver.

### Professional Memberships

Member, American Thoracic Society  
European Cystic Fibrosis Society

### Awards & Recognition

2020: American Society for Clinical Investigation, Elected Member  
2018: ATS Fellow, Inaugural Class, American Thoracic Society, New York, NY  
2017: Founder's Award, United States Adult Cystic Fibrosis Association, Indianapolis, IN  
2016: Physician of the Year, Colorado Society for Respiratory Care, Denver, CO  
2015: Science Transforming Life Award, National Jewish Health, Denver, CO  
2014: Viola Vestal Coulter Research Fellow Award  
2009: Cystic Fibrosis Research Institute Professional of the Year Award  
2009: Selected participant, AAMC Early Career in Medicine Early Career Women Faculty Professional Development Seminar  
2008: Clinical Trials Center New Investigator of the Year Award  
2006: Duke University Pulmonary Fellowship Scientific Achievement Award  
2005: 2nd Place, Fellows' Clinical Research Presentations, Respiratory Disease Young Investigators Forum  
2003: Cystic Fibrosis Foundation Clinical Fellowship

### Publications

Heijerman HGM, \* McKone EF\*, Downey DG, Braeckel E, Rowe SM, Tullis E, Mall M, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, **Taylor-Cousar JL\***, and McCoy K\* on behalf of the VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the *F508del* mutation: a double-blind, randomised, phase 3 trial. **\*equal contributions** *Lancet*. 2019 Oct 30. pii: S0140-6736(19)32597-8. doi: 10.1016/S0140-6736(19)32597-8. PMID: 31679946

Middleton PG\*, Mall MA\*, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, **Taylor-Cousar JL**, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM\*\* and Jain R\*\* for the VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation. *New Eng J Med*. 2019. *Epub ahead of print*

Downey DG and **Taylor-Cousar JL**. Challenges and opportunities in the development of future CFTR modulator options for people with CF. PMID: 31672556

Keating D, Sass L, Burr L, Daines C, Rowe S, Savage J, Simard C, Xuan F, Van Goor F, Robertson S, McKee C, Waltz D, Marigowda G, and **Taylor-Cousar JL (corresponding author)**. VX-445 in Combination with Tezacaftor-Ivacaftor in Phe508del Homozygous and Heterozygous Patients with Cystic Fibrosis. *N Engl J Med* 2018; 379:1612-1620 DOI: 10.1056/NEJMoa1807120 PMID: 30334692

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone E, Plant B, Paris D, Ramsey B, **Taylor-Cousar JL**, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. Triple Combination of VX-659/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and One or Two *F508del-CFTR* Alleles. *N Engl J Med* 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119 PMID: 303334693

### Doctor's Contact Information

Office: 877.225.5654

## Locations

National Jewish Health Main Campus  
1400 Jackson St.

Denver, CO 80206

Saint Joseph Hospital  
1835 Franklin Street

Denver, CO 80218